HomeSGX-LISTED COMPANIESEllipsiz Ltd: FY2025 Financial Results and Dividend Announcement

Ellipsiz Ltd: FY2025 Financial Results and Dividend Announcement

Published on

spot_img

Ellipsiz Ltd experienced a notable financial turnaround in FY2025, transitioning from an overall loss to a profit for the year. This positive shift was primarily driven by increased revenue from continuing operations, especially within its Distribution and Services Solutions segment. The Group also reported a significant gain from the strategic disposal of a business unit, the Automated Precision System Solutions segment. Furthermore, Ellipsiz diversified its portfolio by launching new indoor golf simulator operations in the sports, recreational, and lifestyle sector.

• A major business unit was strategically divested, reshaping the Group’s operational focus

• New ventures were launched in the sports and leisure industry, marking a diversification effort

• The Group’s overall financial performance saw a substantial turnaround from the prior year

LISTEN TO THE PODCAST BELOW:

Latest articles

Top Glove Q3 FY2026 Earnings Rise Despite Fluctuating Material Costs

Resilient Growth and Strategic Agility Top Glove Corporation has reported a remarkable 138% year-on-year surge...

AstraZeneca invests US$20M to curb Malaysia chronic disease burden

AstraZeneca is scaling up early screening and clinical research efforts in Malaysia as the...

AstraZeneca expands diagnostics and AI to tackle late-stage cancer deaths

AstraZeneca is sharpening its long-term AstraZeneca cancer strategy with a combination of heavy research...

AstraZeneca deploys AI to cut drug timelines by 30% and boost survival

AstraZeneca is stepping up its investment in AI drug discovery to shorten treatment timelines...

More like this

Top Glove Q3 FY2026 Earnings Rise Despite Fluctuating Material Costs

Resilient Growth and Strategic Agility Top Glove Corporation has reported a remarkable 138% year-on-year surge...

AstraZeneca invests US$20M to curb Malaysia chronic disease burden

AstraZeneca is scaling up early screening and clinical research efforts in Malaysia as the...

AstraZeneca expands diagnostics and AI to tackle late-stage cancer deaths

AstraZeneca is sharpening its long-term AstraZeneca cancer strategy with a combination of heavy research...